InMode Ltd. (INMD)
Automate Your Wheel Strategy on INMD
With Tiblio's Option Bot, you can configure your own wheel strategy including INMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INMD
- Rev/Share 5.7069
- Book/Share 9.0086
- PB 1.6196
- Debt/Equity 0.009
- CurrentRatio 8.7346
- ROIC 0.2188
- MktCap 1014861433.0
- FreeCF/Share 1.7657
- PFCF 8.3588
- PE 5.7072
- Debt/Assets 0.0079
- DivYield 0
- ROE 0.2501
- Rating A+
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | INMD | BTIG Research | Buy | Neutral | -- | -- | April 29, 2025 |
| Downgrade | INMD | Robert W. Baird | Outperform | Neutral | $22 | $16 | April 28, 2025 |
| Initiation | INMD | BTIG Research | -- | Buy | -- | $25 | Oct. 17, 2024 |
News
DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral
Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI , May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO.
Read More
InMode to Present at Upcoming Investor Conferences and Events
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral
YOKNEAM, Israel , May 7, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences: BNP 3rd Annual Aesthetics Day Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer Format: Virtual fireside chat moderated by Navann Ty, Lead Equity Analyst and one-on-one meetings When: Monday, May 19, fireside chat at 11:00 am ET A live webcast of the presentation can be accessed here.
Read More
InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
IRVINE, Calif. , May 6, 2025 /PRNewswire/ -- InMode Ltd.
Read More
InMode: Equity Value Hinges On Cash, Not Future Prospects (Rating Downgrade)
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Negative
InMode's Q1 2025 earnings reveal a 3% YoY revenue decline and margin compression, signaling continued macroeconomic pressures and underutilization of installed platforms. Management's revised 2025 guidance lowers profitability expectations, reflecting ongoing challenges in the U.S. market and less profitable international expansion. Despite a strong balance sheet, past strategic missteps and ineffective cash allocation raise concerns about future shareholder value and growth prospects.
Read More
Eyes On Park Introduces Revolutionary Envision by InMode System for Advanced Dry Eye Treatment in New York City
Published: April 28, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - April 28, 2025) - Eyes On Park, a leading optometry practice in Gramercy Park, announces the introduction of the cutting-edge Envision by InMode system for comprehensive dry eye treatment. Dr. Irina Shiyan and her team now offer this advanced, non-invasive technology that combines Forma-I radiofrequency and Lumecca-I intense pulsed light therapies to address the root causes of dry eye disease, not just the symptoms.
Read More
InMode Ltd. (INMD) Q1 2025 Earnings Call Transcript
Published: April 28, 2025 by: Seeking Alpha
Sentiment: Neutral
InMode Ltd. (NASDAQ:INMD ) Q1 2025 Earnings Conference Call April 28, 2025 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - CEO Yair Malca - CFO Conference Call Participants Matt Miksic - Barclays Danielle Antalffy - UBS Matt Taylor - Jefferies Caitlin Cronin - Canaccord Genuity Mike Matson - Needham & Company Sam Eiber - BTIG Dane Reinhardt - Baird Operator Good day, and welcome to InMode's First Quarter 2025 Earnings Results Conference Call.
Read More
InMode (INMD) Lags Q1 Earnings Estimates
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Negative
InMode (INMD) came out with quarterly earnings of $0.31 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.45 per share a year ago.
Read More
InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025.
Read More
InMode (INMD) Soars 6.8%: Is Further Upside Left in the Stock?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
InMode (INMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
InMode: Strategic Capital Allocation Unlocks Shareholder Value (Rating Upgrade)
Published: April 03, 2025 by: Seeking Alpha
Sentiment: Positive
I upgrade InMode to Buy due to improved capital allocation, including significant share buybacks and potential for record dividends. Despite a 20% revenue decline in 2024, InMode remains a strong cash generator, with $600 million in cash. Conservative DCF valuation suggests a fair value of $21.67 per share, implying a 22.5% potential upside from current levels.
Read More
3 Undervalued MedTech Stocks to Buy for 2025 Gains Amid S&P 500 Rally
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Three discounted MedTech stocks to gain from the market rebound are PAHC, FMS and INMD.
Read More
Is InMode (INMD) Stock Undervalued Right Now?
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
InMode: Plastic Surgery Boom, Cash Flow, And Cheap
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Positive
InMode is significantly undervalued, with strong cash flow, international expansion, and investments in research and marketing driving future revenue and free cash flow growth. The company benefits from the booming non-invasive plastic surgery market, expected to grow at a 14% CAGR from 2023 to 2030. INMD's stock repurchase program and substantial investments in bonds and bank deposits are expected to boost stock price and financial stability.
Read More
About InMode Ltd. (INMD)
- IPO Date 2019-08-08
- Website https://www.inmodemd.com
- Industry Medical - Devices
- CEO Mr. Moshe Mizrahy
- Employees 599